Table 2.
Baseline demographics and clinical characteristics in the enrolled subjects.
| Outcomes | EG (n = 18) Mean (SD)/Median (IQR) |
CG (n = 17) Mean (SD)/Median (IQR) |
p-Value |
|---|---|---|---|
| Height (cm) | 158.3 (4.7) | 0.853 | |
| 158.1 (4.7) | 158.4 (4.8) | ||
| Age (years) | 50.4 (7.9) | 0.015 * | |
| 53.6 (5.2) | 47.1 (9.0) | ||
| Weight (kg) | 59.8 (9.3) | 0.898 | |
| 60 (9.2) | 59.59 (9.7) | ||
| BMI (kg/m2) | 24.0 (3.6) | 0.879 | |
| 24.1 (3.8) | 23.9 (3.6) | ||
| Disease duration (years) | 5.6 (7.0) | 0.987 | |
| 5.3 (6.9) | 6.0 (7.3) | ||
|
Body function
and structure |
|||
| UE strength (Rt) | 43.4 (12.4) | 51.0 (8.6) | 0.046 * |
| UE strength (Lt) | 44.4 (8.9) | 47.2 (8.9) | −0.366 |
| LE strength (Rt) | 55.1 (7.2) | 54.4 (6.5) | 0.768 |
| LE strength (Lt) | 54.3 (6.4) | 53.0 (5.6) | 0.508 |
| CSA-RF (Rt) | 1.0 (0.3) | 1.4 (0.8) | 0.043 * |
| CSA-RF (Lt) | 0.9 (0.2) | 1.4 (0.8) | 0.025 * |
| Activity level | |||
| 6MWT | 508.6 (48.5) | 494.7 (49.9) | 0.407 |
| STS | 15.5 (14.8:19.3) | 15.0 (14.0:18.0) | 0.499 |
| Borg | 2.0 (1.8:3.0) | 2.0 (1.5:3.0) | 0.884 |
| Participation | |||
| Physical function | 71.4 (12.5) | 72.7 (17.0) | 0.803 |
| Mental health | 53.9 (9.8) | 58.6 (6.8) | 0.111 |
* Significantly different (p < 0.05). EG, experimental group; CG, control group; UE, upper extremity; LE, lower extremity; CSA-RF, cross-sectional area of the rectus femoris.